Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy

Laura I. Marquez Loza,[1,2] Ashley L. Cooney,[1,2] Qian Dong,[1,2] Christoph O. Randak,[1,2] Stefano Rivella,[3] Patrick L. Sinn,[1,2] and Paul B. McCray, Jr.[1,2]

[1]Stead Family Department of Pediatrics, The University of Iowa, Iowa City, IA 52242, USA; [2]Pappajohn Biomedical Institute and the Center for Gene Therapy, The University of Iowa, Iowa City, IA 52242, USA; [3]Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

Despite significant advances in cystic fibrosis (CF) treatments, a one-time treatment for this life-shortening disease remains elusive. Stable complementation of the disease-causing mutation with a normal copy of the CF transmembrane conductance regulator (*CFTR*) gene fulfills that goal. Integrating lentiviral vectors are well suited for this purpose, but widespread airway transduction in humans is limited by achievable titers and delivery barriers. Since airway epithelial cells are interconnected through gap junctions, small numbers of cells expressing supraphysiologic levels of CFTR could support sufficient channel function to rescue CF phenotypes. Here, we investigated promoter choice and *CFTR* codon optimization (co*CFTR*) as strategies to regulate *CFTR* expression. We evaluated two promoters—phosphoglycerate kinase (PGK) and elongation factor 1-α (EF1α)—that have been safely used in clinical trials. We also compared the wild-type human *CFTR* sequence to three alternative co*CFTR* sequences generated by different algorithms. With the use of the CFTR-mediated anion current in primary human CF airway epithelia to quantify channel expression and function, we determined that EF1α produced greater currents than PGK and identified a co*CFTR* sequence that conferred significantly increased functional CFTR expression. Optimized promoter and *CFTR* sequences advance lentiviral vectors toward CF gene therapy clinical trials.

INTRODUCTION

Since mutations in cystic fibrosis (CF) transmembrane conductance regulator (*CFTR*) were identified as the cause of CF,[1] gene addition has held the promise of a one-time definitive treatment for this common life-shortening disease. Several CF gene therapy clinical trials using adenovirus,[2,3] adeno-associated virus (AAV),[4,5] or plasmid-based vectors[6–8] have taken place, but none progressed to phase III. Lentiviral vectors are well suited for CF gene therapy because of their large packaging capacity, long-term expression, safety profile, and promising results in CF animal models.[9–11] Despite these attractive features, clinical trials using lentiviral vectors have yet to be initiated.

The use of lentiviral vectors for the treatment of CF airway disease has been limited, in part, by the transduction efficiency of airway epithelial cells. Most lentiviral vectors used for clinical applications are pseudo-typed with the vesicular stomatitis virus glycoprotein (VSV-G) because it produces high titer vectors with broad cell tropism.[12] However, VSV-G receptors in airway epithelial cells are located predominantly on the basolateral surface[13,14] and require additional steps, such as disruption of tight junctions,[15–17] to achieve meaningful transduction. Alternative glycoproteins from filoviruses,[18,19] baculovirus,[14,20] influenza,[21] and Sendai virus[22–24] confer improved apical surface tropism. Compared to adenoviral or AAV vectors, however, the maximum achievable lentiviral vector titers with current manufacturing methods are lower. The achievable lentiviral titers, combined with the large surface area of human airway epithelium, are a driving force for alternative strategies to increase lentiviral-based *CFTR* expression.

The airway epithelium is a complex tissue consisting of a variety of cell types that are interconnected and electrochemically coupled through gap junctions.[25–28] Ciliated cells, one of the most abundant cell types, were previously thought to collectively produce the majority of CFTR function in surface airway epithelium, with low abundance per ciliated cell.[29] The recent discovery of pulmonary ionocytes, however, revealed that this rare cell type, which comprises ∼1% of all proximal airway epithelial cells, produces ∼50% of all *CFTR* messenger RNA (mRNA) transcripts.[30,31] Although the physiologic role and function of pulmonary ionocytes are under investigation, the natural occurrence of a rare cell type with high CFTR abundance supports the notion of vector-conferred gene addition as a therapeutic strategy. Additionally, a recent study provided detailed analysis of the regional distribution of *FOXI1*-expressing cells and also presented evidence that basal cells and secretory cells express *CFTR* transcripts.[32] Thus, we reasoned that increasing *CFTR* expression in a small proportion of cells successfully transduced by lentiviral vectors could provide sufficient protein function to correct CF

Correspondence: Paul B. McCray, Jr., Stead Family Department of Pediatrics, The University of Iowa, 169 Newton Rd., 6320 PBDB, Iowa City, IA 52242, USA.
E-mail: paul-mccray@uiowa.edu

A HIV-PGK-WT *CFTR*

| 5' LTR | PGK > | WT *CFTR* | Ank | 3' SIN LTR |

HIV-PGK-co*CFTR* 3

| 5' LTR | PGK > | co*CFTR* 3 | Ank | 3' SIN LTR |

HIV-PGK-GFP

| 5' LTR | PGK > | GFP | Ank | 3' SIN LTR |

B HIV-EF1α-WT *CFTR*

| 5' LTR | EF1α > | WT *CFTR* | Ank | 3' SIN LTR |

HIV-EF1α-GFP

| 5' LTR | EF1α > | GFP | Ank | 3' SIN LTR |

Figure 1. Schematic of the vectors used in this study

The integrated forms of the HIV-based lentiviral vectors are shown. Two versions of vectors expressing wild-type (WT) cystic fibrosis (CF) transmembrane conductance regulator (*CFTR*), codon-optimized *CFTR* version 3 (co*CFTR*3), or GFP were compared. (A and B) Only the promoters used to drive transgene expression differ between the two versions, either (A) human phosphoglycerate kinase (PGK), or (B) human elongation factor 1-α (EF1α). A human ankyrin 1 (Ank) insulator element in the reverse orientation is present within the self-inactivating (SIN) 3′ LTR. Vectors shown are not to scale.

phenotypes. Gene expression can be modulated through promoter choice and codon usage. To develop a lentiviral vector that provides optimal *CFTR* expression, a direct comparison of these two vector components in a relevant cell culture model is needed.

Promoter strength varies among different species and cell types.[33,34] Overexpression of CFTR with a strong constitutive promoter, such as cytomegalovirus (CMV), can cause protein mis-sorting to the basolateral membrane.[35] Alternative promoters include human phosphoglycerate kinase (PGK) and elongation factor 1-α (EF1α), which are associated with reduced rates of gene silencing and low genotoxic risk when used with integrating vectors.[36–38] In addition, they were used in clinical trials with no adverse effects reported to date,[39–41] making them ideal candidates for cell-based pre-clinical studies.

Codon optimization is another strategy to increase transgene expression in clinical trials for genetic diseases.[41–47] The genetic code is degenerate; therefore, multiple nucleotide sequences can yield the same final amino acid sequence. Codon optimization utilizes this feature of the genetic code to improve gene expression. Several factors related to nucleotide sequence influence gene expression, including tRNA abundance,[48] total GC content,[49] GC content at the third nucleotide position of a codon (GC$_3$),[49–51] and CpG content.[52] A combination of these and other factors, such as predicted secondary structure, translation speed, and cryptic splice sites, are used by proprietary and publicly available algorithms to codon optimize genes. In addition, most codon optimization algorithms increase the codon adaptive index (CAI), a measure of how closely the codons in a gene match those of highly expressed genes in a particular species.[53]

Because each algorithm uses different parameters and produces a unique final sequence, we compared three different codon-optimized sequences for efficacy in a model cell line. We then validated the best performing sequence in primary human airway epithelial cells derived from CF donors.

RESULTS

To compare the amount of protein produced by vectors with expression driven by the PGK or EF1α promoters, we cloned GFP into HIV-based lentiviral vectors that differed only in the promoter (HIV-PGK-GFP and HIV-EF1α-GFP) (Figure 1) and produced VSV-G-pseudotyped vectors. Basal cells, a progenitor cell type of the conducting airways, from human non-CF donors were transduced with these vectors at MOIs of 0.04, 0.4, and 4 and analyzed by flow cytometry. Similar numbers of GFP$^+$ cells were observed with both vectors, ranging from <1% to >80%, among the different MOIs, 3−5 days post-transduction (Figure 2A), and after 4 weeks of differentiation in air-liquid interface culture conditions (Figure 2B). Cells transduced with HIV-EF1α-GFP, however, showed higher mean fluorescence intensity (MFI) at every dose tested compared to cells transduced with HIV-PGK-GFP, and this difference was statistically significant at MOI 4 (Figures 2A, $p < 0.0006$, and 2B, $p < 0.002$).

We next transduced basal cells from CF donors with HIV-PGK-wild-type (WT)*CFTR*, HIV-EF1α-WT*CFTR*, or HIV-PGK-GFP. In these experiments, cells were seeded onto permeable filters at the time of transduction and allowed to differentiate at an air-liquid interface for a minimum of 4 weeks. The number of transduced cells present after differentiation was estimated by quantifying GFP$^+$ cells by flow cytometry and ranged from <1% to 85% (Figure 2C). The CFTR-mediated chloride current was measured in Ussing chambers (Figure 2D). First, epithelial sodium channel (ENaC) and non-CFTR chloride channels were sequentially inhibited using amiloride and 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid (DIDS), respectively. CFTR was then stimulated with forskolin and 3-isobutyl-1-methylxanthine (F&I), and the change in short circuit current (ΔI_{SC}) was calculated. Finally, CFTR was inhibited with GlyH-101 (GlyH). At all MOIs tested, HIV-EF1α-WT*CFTR* produced more CFTR current, on average, compared to HIV-PGK-WT*CFTR,* but the difference was not statistically significant (Figure 2E). A condition using HIV-EF1α-GFP was not included in these experiments due to the limited number of primary cells available from each CF donor.

CFTR is composed of two sets of transmembrane domains (TMD1 and TMD2), two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain (RD) (Figure 3A). To investigate the efficacy of different codon-optimization strategies, we codon optimized *CFTR* (co*CFTR*) using three different methods. Previous studies suggest that codon usage affects CFTR co-translational folding, and these effects may be domain specific.[54] Therefore, to determine the effect of codon optimization on a single domain, only the first domain, TMD1, was codon optimized in co*CFTR*1. The entire gene was optimized for co*CFTR*2 and co*CFTR*3 (Figure 3B). A proprietary algorithm (GenScript) was used for co*CFTR*2 and a publicly available algorithm

Figure 2. EF1α drives higher transgene expression in primary human airway epithelial cells compared to PGK

(A and B) Basal progenitor cells from five human donors without CF (non-CF) donors were transduced with lentiviral vectors HIV-PGK-GFP or HIV-EF1α-GFP at MOI 0.04, 0.4, or 4. GFP⁺ cells and mean fluorescence intensity (MFI) were quantified by flow cytometry (A), 3–5 days post-transduction and (B) after 4 weeks of differentiation. No significant difference was observed in the number of GFP⁺ cells transduced by either vector at any dose. A significant increase in MFI was observed in cells transduced with HIV-EF1α-GFP compared to HIV-PGK-GFP at MOI 4 at both time points (*p < 0.0006, **p < 0.002). Similarly, basal cells from four human CF donors were transduced with lentiviral vectors HIV-PGK-WT*CFTR*, HIV-EF1α-WT*CFTR*, or HIV-PGK-GFP. (C) After 4 weeks of differentiation under air-liquid interface conditions, the number of remaining transduced cells was estimated through quantification of GFP⁺ cells by flow cytometry. (D) Transepithelial Cl⁻ current was measured in Ussing chambers. ENaC and non-CFTR chloride channels were inhibited with sequential addition of amiloride and 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid (DIDS), respectively, prior to activation of CFTR channels with cyclic AMP (cAMP) agonists forskolin and 3-isobutyl-1-methylxanthine (F&I). CFTR-specific current was verified by addition of CFTR inhibitor GlyH-101 (GlyH). (E) The short circuit current change (ΔI_{SC}) in response to F&I and GlyH was calculated. No significant difference between the two vectors was observed at any dose. Current measurements in cultures from one donor in two treatment groups (HIV-EF1α-WT*CFTR* MOI 0.04 and 4) could not be completed due to unsuccessful differentiation. Points on the graph represent the average of 1–3 epithelia. Each donor is represented by a unique symbol. Mean ± SE is shown.

co*CFTR*3, with co*CFTR*3 having a GC₃ content of nearly 100% (Figure 3D).

WT *CFTR* and all co*CFTR* cDNAs were each expressed from the mammalian expression vector pcDNA3.1(+) to compare their expression. Human embryonic kidney (HEK)293 cells were transfected, and 72 h later, total cellular mRNA and protein were collected. A GFP expression plasmid served as a control. Different forms of CFTR can be detected by western blot based on their glycosylation patterns, including bands B and C.[56] Band C is the fully glycosylated form and was the most abundant form found in cells transfected with WT *CFTR* (Figure 4A). Bands B and C abundance increased in cells transfected with any of the co*CFTR* sequences, but only band B was significantly more abundant (p < 0.007), leading to a decrease in C/B ratio (p < 0.02). mRNA abundance was measured by qRT-PCR. Although all co*CFTR* sequences resulted in higher average mRNA content over WT *CFTR*,

(JCat)[55] for co*CFTR*3. As expected, all strategies increased the CAI compared to WT *CFTR*, but the amino acid sequence remained the same (Table 1). The total GC content increased in all codon-optimized sequences compared to WT *CFTR*, but co*CFTR*3 had the highest increase (from 42% to 64%; Figure 3C). The GC₃ content also increased compared to WT *CFTR* in the single codon-optimized domain of co*CFTR*1 and throughout all domains of co*CFTR*2 and

Figure 3. Comparison of three different co*CFTR* sequences

Different approaches to codon optimization were used to generate co*CFTR*1, co*CFTR*2, and co*CFTR*3. (A) CFTR is composed of five distinct protein domains, including two transmembrane domains (TMD1 and TMD2), two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain (RD). (B) The percent similarity of codons compared to WT *CFTR* is shown by protein domain. (C) The individual nucleotide content for each sequence was quantified. (D) The percentage of codons using a G or C at the third nucleotide position (GC$_3$) for each sequence is shown by protein domain.

the fold increases were not statistically significant for any sequence (Figure 4B).

To investigate the effect of codon optimization on protein function, a cell line that formed a polarized epithelium was required. Fischer rat thyroid (FRT) cells are a useful model for the study of CFTR function, because they express no endogenous CFTR and form a polarized epithelium when grown at air-liquid interface culture conditions.[57] These epithelia are then used to measure transepithelial anion currents in Ussing chambers. FRT cells were electroporated with pcDNA3.1(+) plasmids expressing WT *CFTR*, one of the co*CFTR* sequences, or a GFP control plasmid and seeded onto semipermeable membranes. 1 week later, transepithelial chloride current was measured under apical low chloride gradient conditions (Figure 4C). Compared to WT *CFTR*, co*CFTR*1 did not increase function, whereas co*CFTR*2 showed a modest increase, and co*CFTR*3 led to a significant increase (Figure 4D; $p < 0.0001$). Western blots performed in transfected FRT cells revealed a similar expression pattern as that observed in HEK293 cells, with all co*CFTR* sequences producing more CFTR compared to WT *CFTR* (Figure S1). Densitometry analysis, however, was not reliable due to the low abundance of WT CFTR.

Since expression of co*CFTR*3 produced the greatest increase in protein function in the FRT cell assay, we next sought to determine if similar effects would be achieved in primary CF human airway epithelial cells. We introduced co*CFTR*3 into the same lentiviral vector backbone used in the promoter comparison experiments (Figure 1A). Given the significant increase in I$_{SC}$ observed with co*CFTR*3 compared to WT *CFTR* in FRT cells, PGK was chosen since it produced lower currents than EF1α, on average, and would allow us to more easily detect any effects of codon optimization. For the same reason, based on the I$_{SC}$ dose response observed in the promoter comparison experiments (Figure 2E), MOIs ≤ 1 were used. Basal cells

from human CF donors were transduced with HIV-PGK-WT*CFTR*, HIV-PGK-co*CFTR*3, or HIV-PGK-GFP at four different MOIs (0.1, 0.25, 0.5, and 1). Epithelial cultures were transduced at the time of seeding and allowed to differentiate for four weeks (Figure S2).[58] We predicted these doses would achieve a range of transduction efficiencies, allowing us to determine an optimal MOI to achieve non-CF levels of anion current. GFP$^+$ cells were quantified by flow cytometry in epithelia transduced with the GFP vector to estimate the number of transduced cells present after differentiation. Donor-dependent differences in transduction permissiveness were observed, resulting in ~2%–91% GFP$^+$ cells at the doses tested (Figure 5A). Epithelia transduced with *CFTR* vectors were mounted in Ussing chambers and transepithelial anion currents measured (Figure 5B). HIV-PGK-co*CFTR*3 conferred significantly higher CFTR-dependent transepithelial chloride current at the lowest dose (MOI 0.1, $p < 0.04$) and higher bicarbonate currents at the highest doses (MOI 0.05 and 1, $p < 0.02$) compared to HIV-PGK-WT*CFTR* (Figures 5C and 5D).

Previous studies demonstrate that synonymous codon substitutions may affect folding dynamics and could change protein function.[59,60] The marked increase in chloride current observed with FRT cells (Figure 4C), combined with the significant increase in the immature (band B) form of CFTR (Figure 4A), and the increase in CFTR anion currents in primary airway epithelia observed with co*CFTR*3 (Figures 5C and 5D) raised the possibility that co*CFTR*3 could have channel properties different from WT CFTR. To study the single channel properties of WT CFTR and co*CFTR*3, we performed patch-clamp studies in HEK293 cells transfected with WT *CFTR* or co*CFTR*3 cDNA (Figure 6A). No significant differences were found in mean open state probability (Figure 6B), burst duration (BD) (Figure 6C), or interburst interval (IBI) (Figure 6D). These findings indicate that the CFTR channels produced by co*CFTR*3 have the same properties as those produced by WT *CFTR*. Furthermore, the increase in CFTR band B associated with co*CFTR* might be expected since protein processing mechanisms are downstream of those thought to be affected by codon optimization. Together, these results confirmed that co*CFTR*3 produces more functional CFTR in CF primary human

Table 1. Codon usage of *CFTR* sequences

				WT CFTR	coCFTR1[a]	coCFTR2[b]	coCFTR3
Ala	G	C	G	6	3	4	0
			A	34	26	20	0
			T	27	20	22	0
			C	16	34	37	83
Arg	G	C	G	16	13	17	0
			A	37	24	22	0
	C	G	G	8	4	13	0
			A	9	33	7	0
			T	3	2	7	0
			C	5	2	12	78
Asn	A	A	T	25	21	24	0
			C	29	33	30	54
Asp	G	A	T	38	32	26	0
			C	20	26	32	58
Cys	T	G	T	8	6	10	0
			C	10	12	8	18
Gln	C	A	G	31	37	47	67
			A	36	30	20	0
Glu	G	A	G	30	45	61	93
			A	63	48	32	0
Gly	G	G	G	16	10	21	0
			A	38	30	18	0
			T	15	14	13	0
			C	15	30	32	84
His	C	A	T	11	9	7	0
			C	14	16	18	25
Ile	A	T	A	33	26	14	0
			T	50	39	46	0
			C	36	54	59	119
Leu[b]	T	T	G	34	27	29	0
			A	37	29	13	0
	C	T	G	37	26	72	183
			A	19	12	9	0
			T	32	20	23	0
			C	24	69	38	0
Lys	A	A	G	35	47	53	92
			A	57	45	39	0
Met[a]	A	T	G	38	39	38	38
Phe[b]	T	T	T	47	35	37	0
			C	38	50	47	85
Pro	C	C	G	1	0	5	0
			A	13	21	12	0
			T	20	15	13	0
			C	11	9	15	45

(*Continued on next page*)

Table 1. Continued

				WT CFTR	coCFTR1[a]	coCFTR2[b]	coCFTR3
Ser	A	G	T	19	15	18	0
			C	24	20	28	123
	T	C	G	4	3	9	0
			A	29	22	24	0
			T	30	23	26	0
			C	17	40	18	0
Thr	A	C	G	3	3	6	0
			A	33	31	18	0
			T	32	29	26	0
			C	15	20	33	83
Trp	T	G	G	23	23	23	23
Tyr	T	A	T	22	15	15	0
			C	18	25	25	40
Val[a]	G	T	G	36	46	48	89
			A	12	11	9	0
			T	23	17	12	0
			C	18	14	20	0
Stop	T	G	A	0	0	0	0
	T	A	G	1	1	1	0
			A	0	0	0	1
			Total	1481	1481	1481	1481
			CAI	0.74	0.76	0.80	0.99

The codon adaptive index (CAI) is higher in all coCFTR sequences compared to WT CFTR. coCFTR1 and coCFTR2 were codon optimized with single amino acid changes that do not affect protein function.
[a]coCFTR1 substitutes methionine for valine at position 1475.
[b]coCFTR2 substitutes leucine for phenylalanine at position 833.

airway epithelial cells, reaching the range of non-CF anion currents at MOIs < 1 without changing CFTR channel properties.

DISCUSSION

Several studies have attempted to approximate the proportion of airway epithelial cells that needs to express functional CFTR to correct CF phenotypes, with results ranging from 5% to 50%.[35,61–64] Achieving a transduction efficiency as high as 50% in intact airway epithelia with lentiviral vectors is challenging. *In vivo* studies in the CF pig model demonstrate that some phenotypic tissue correction is achievable, even if transgene expression was below detectable levels by mRNA quantification.[10] Because airway epithelia are electrochemically coupled through gap junctions, we postulated that supra-physiologic levels of CFTR expression in a small number of cells could be therapeutic.

Promoter choice and codon optimization are two strategies that are often employed to increase transgene expression in gene therapy applications. We compared two constitutive promoters, PGK and EF1α, which are effective at driving expression of mammalian genes and are safely used in clinical trials.[39–41] In CF airway epithelia, the CFTR currents achieved using the EF1α promoter trended higher than those attained with PGK, on average, but did not reach statistical significance. Of note, approximately 50% transduction efficiency was obtained with both vectors at MOI 4, and the CFTR-dependent currents at this dose reached non-CF levels. This is likely related to anion movement through gap junctions. Additionally, others have shown that the rate-limiting step for CFTR-dependent chloride secretion is the abundance of the NKCC1 cotransporter at the basolateral membrane.[35,63,65] When quantifying GFP expression in non-CF cells, similar numbers of GFP+ cells were obtained with PGK or EF1α, and the MFI achieved with the EF1α promoter was higher on average at every dose, reaching statistical significance at the highest dose. The proportion of GFP+ non-CF cells, measured 3−5 days post-transduction, was within expected levels based on a similar transduction protocol.[58] The proportion of GFP+ cells present in CF and non-CF cells after 4 weeks of differentiation, however, represents differences in individual cell division rates over that time, which may explain why some values exceed the theoretical maximum for a given MOI and why the number of transduced cells appears to change over time in some epithelia.

Codon optimization has been used to increase expression of other genes in several therapeutic applications[66–68] and has been

Figure 4. co*CFTR* increases protein, mRNA, and transepithelial chloride current

293T human embryonic kidney cells (HEK293) cells were transfected with pcDNA3.1(+) plasmid expressing WT *CFTR*, co*CFTR*1, co*CFTR*2, co*CFTR*3, or a GFP control. Protein and mRNA were isolated from transfected cells. (A) CFTR abundance was quantified by western blot. Bands B and C glycosylation forms were detected, and vinculin was used as a loading control. Densitometry analysis demonstrated no significant increase for CFTR band C, a significant increase in CFTR band B (*$p \leq 0.007$), and a significant decrease in C/B ratio (**$p \leq 0.02$) with co*CFTR*1, co*CFTR*2, and co*CFTR*3 compared to WT *CFTR*. (B) *CFTR* mRNA quantification by qRT-PCR was performed using primers that target a portion of the polyadenylation sequence present in all plasmids, and GAPDH was used to normalize expression. No statistically significant increase in mRNA abundance compared to WT *CFTR* was observed with any of the codon-optimized sequences. To test protein function, Fischer rat thyroid (FRT) cells were electroporated with the same plasmids and grown at air-liquid interface culture conditions. 1 week later, transepithelial chloride current was measured in Ussing chambers. (C) Apical low chloride gradient was established, and once stable, CFTR channels were activated with cAMP agonists F&I. CFTR-specific current was verified by inhibiting CFTR with GlyH. (D) The change in current (ΔI_T) in response to F&I and GlyH was measured. We observed a significant increase in CFTR-dependent current only with co*CFTR*3 compared to WT CFTR (***$p < 0.0001$). Mean ± SE is shown. See also Figure S1.

investigated as a strategy to improve non-viral approaches to CF gene therapy.[69] Here, we compared different codon optimization strategies in cell line models and determined that each strategy conferred a unique increase in mRNA, protein, and protein function, evidenced by a CFTR-dependent transepithelial chloride current. Codon optimization of a single protein domain failed to improve expression over WT *CFTR*. Of two different strategies to codon optimize the entire gene, the one that resulted in higher GC and GC$_3$ content, co*CFTR*3, also yielded the greatest increase in protein function, suggesting that these may be important characteristics for co*CFTR*.

When comparing WT *CFTR* and co*CFTR*3 in primary human CF airway epithelia transduced with a lentiviral vector, HIV-PGK-co*CFTR*3 significantly increased chloride currents at the lowest vector dose tested (MOI 0.1). As expected, we observed a dose-dependent increase in the chloride current with HIV-PGK-WT*CFTR*, but very

similar chloride currents were observed at all doses tested with HIV-PGK-co*CFTR*3. This is consistent with previous studies indicating that chloride currents generated by epithelia composed entirely of non-CF cells can be achieved in epithelial sheets consisting of ~50% non-CF and 50% CF cells and remain stable even when more non-CF cells are added.[63] This suggests that the maximum chloride current for a given epithelium was achieved at MOI 0.1, explaining why no additional increase is seen at higher MOIs. Likewise, this could also explain why the chloride current difference between HIV-PGK-WT*CFTR* and HIV- EF1α-WT*CFTR* was not significant at any dose, but GFP expression was significantly higher with EF1α at the highest dose. That is, CFTR-mediated chloride current as a measure of CFTR expression has a lower maximum limit than MFI for GFP expression. CFTR bicarbonate currents, however, continued to increase with CFTR abundance,[63] which is consistent with the dose-dependent increase observed with HIV-PGK-WT*CFTR* and HIV-PGK-co*CFTR*3, and the difference between the two was

Figure 5. co*CFTR* increases transepithelial anion current in human CF primary airway epithelial cells

CF progenitor basal cells from six donors were transduced with lentiviral vectors HIV-PGK-WT*CFTR*, HIV-PGK-co*CFTR*3, or HIV-PGK-GFP at MOI 0.1, 0.25, 0.5, and 1 and seeded on polycarbonate membranes. Cells were allowed to differentiate for 4 weeks in air-liquid interface culture conditions. (A) Epithelia that received GFP were used to estimate the proportion of cells expressing the transgene after differentiation by flow cytometry. (B) CFTR transepithelial chloride and bicarbonate short circuit current was measured in Ussing chambers. Changes (ΔI_{SC}) in response to (C) F&I and (D) GlyH were quantified. HIV-PGK-co*CFTR*3 resulted in significantly higher chloride current at MOI 0.1 (*p < 0.04) and higher bicarbonate current at MOI 0.5 and 1 (**p < 0.02) compared to HIV-PGK-WT*CFTR*. Points on the graph represent the average of 2−3 epithelia. Each symbol represents cells from an individual donor. Mean ± SE is shown. See also Figure S2.

One limitation of this work is that VSV-G-pseudotyped lentiviral vectors were used to transduce progenitor basal cells. It is reassuring that CF basal cells expressing exogenous *CFTR* under regulation of a constitutive promoter can differentiate, form epithelia, and support CFTR-mediated transepithelial anion movement, suggesting this could be an effective therapeutic strategy to achieve long-term *CFTR* expression. This strategy could also be used for cell-based therapies.[72] The apical transduction efficiency of intact well-differentiated airway epithelia with VSV-G-pseudotyped lentiviral vectors is low.[13,14] In future studies, lentiviral vectors pseudotyped with an envelope that allows more efficient apical transduction of differentiated epithelia will be required.

significant at the highest doses. Achieving transepithelial anion currents within the range of non-CF at MOI 0.1 with HIV-PGK-co*CFTR*3 is highly relevant for *in vivo* studies since we anticipate likely transducing less than 50% of surface epithelia.

Although EF1α conferred greater WT CFTR-mediated chloride currents and GFP expression, it is important to note that its sequence is over twice the length (∼1.1 kb) of PGK (∼0.5 kb). This is an important consideration when coupled with a large cDNA, such as *CFTR* (∼4.5 kb), since there is an inverse relationship between lentiviral vector titer and insert length.[70,71] The extent to which the extra length of EF1α affects *CFTR* lentiviral vector titers remains to be determined and, if significant, weighed against the increase in CFTR production it provides.

Having identified two independent methods to increase *CFTR* expression, it is tempting to suggest a combinational approach, using EF1α and co*CFTR*3 in the same vector, and we will test that strategy in future studies. However, we speculate that if the effects of each of these strategies are additive, then we may reach the counterproductive threshold. When *CFTR* was overexpressed with the CMV promoter in a large proportion of cells using an adenoviral vector, it led to aberrant localization to the basolateral membrane.[35] If this happens in a small number of cells, then the anion concentration gradient would drive net movement in the desired direction. But, as the proportion of cells with both apical and basolateral CFTR expression increases, the driving force for anion secretion would dissipate.

We identified a promoter and co*CFTR* strategy that significantly increases CFTR-mediated anion transport. Questions remain regarding

Figure 6. Codon optimization of *CFTR* does not change CFTR single channel properties

Patch-clamp studies were performed using inside-out membrane patches from HEK293 transiently expressing WT *CFTR* or co*CFTR*3. (A) Representative tracings are shown. PKA catalytic subunit (22 nM) and ATP (1 mM) were present throughout. Holding voltage was −70 mV. For illustration purposes, traces were digitally low-pass filtered at 50 Hz. c, closed state; o, open state. (B−D) Mean channel open probability, burst duration, and interburst intervals were not different between WT CFTR and coCFTR3. Mean ± SE is shown.

the effects of combining both features in a single vector and the effect of promoter length on vector titers. Ultimately, testing co*CFTR*3 in CF animal models will be needed to determine its efficacy at correcting CF phenotypes. We anticipate that incorporating EF1α, co*CFTR*3, or both could lower the proportion of cells that needs to be successfully targeted by a lentiviral vector and facilitate sufficient gene delivery to provide clinically relevant CF phenotype correction.

MATERIALS AND METHODS
Plasmids
WT *CFTR* and co*CFTR*1 (GenBank: MW222115) in the pcDNA3.1(+) vector were kind gifts from Drs. Jae Seok Yoon and William R. Skach. Only the first 356 amino acids of co*CFTR*1 were codon optimized. co*CFTR*1 contains a valine-for-methionine substitution at position 1475, which does not affect protein function.[73] Codon optimization and synthesis of co*CFTR*2 (GenBank: MW116826) were commercially performed by GenScript in the Bluescript plasmid. co*CFTR*2 contains the leucine-for-phenylalanine substitution at position 833 present in the originally reported *CFTR* sequence,[1] which increases protein solubility but does not affect protein structure.[74] Codon optimization of co*CFTR*3 (GenBank: MW116827) was performed using JCat[55] and was commercially synthesized by GenScript in the HIV-PGK-coCFTR3 vector. co*CFTR*2 and co*CFTR*3 were subcloned into pcDNA3.1(+). HIV-PGK-WTCFTR and HIV-EF1α-GFP were synthesized by GenScript and used to clone HIV-PGK-GFP, HIV-PGK-co*CFTR*3, and HIV-EF1α-WT*CFTR*. The HIV-based vectors used are second generation, self-inactivating (SIN), and contain a human ankyrin 1 element in the reverse orientation within the 3′ long terminal repeat (LTR) that improves long-term expression by avoiding silencing.[75,76]

Codon-optimized sequence comparisons
CFTR domains were defined by the following amino acid positions: TMD1 (1−356), NBD1 (357−678), RD (679−840), TMD2 (841−1,156), and NBD2 (1,157−1,481). Nucleotide content was determined using SeqBuilder Pro 17 (DNASTAR; Lasergene, Madison, WI, USA). Codon usage and GC_3 content were determined using Sequence Manipulation Suite (bioinformatics.org).

Viral vector production
All viral vectors were produced by The University of Iowa Viral Vector Core. Briefly, a triple transfection (psPAX2, VSV-G, and HIV vector) was performed in 293FT (Thermo Fisher Scientific/Gibco, Waltham, MA, USA) cells using the TransIT-Lenti Reagent (Mirus, Madison, WI, USA). Cells were cultured in DMEM, supplemented with 5% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Vector-containing supernatant was collected at 48 and 72 h. After filtration (0.2 μm), vector was concentrated 750-fold by overnight centrifugation (7,000 rpm, 4°C). The vector pellet was resuspended in 4% D-lactose and stored at −80°C. Vectors were titered in HT1080 cells by flow cytometry for GFP vectors or by TaqMan qPCR/digital droplet PCR for *CFTR* vectors using primers: 5′-CGACTGGTGAGTACGCCAAA-3′ and 5′-CGCACCCATCTCTCTCCTTCT-3′ and probe 5′-ATTTTGACTAGCGGAGGC-3′.

FRT electroporation and epithelia formation
FRT cells were cultured in Ham F-12 Coon's modified medium, supplemented with 5% FBS and 1% penicillin/streptomycin at 37°C in a 5% CO_2 humidified environment. 1.2×10^6 FRT cells were electroporated with 4 μg of pcDNA3.1(+) plasmid (Amaxa Nucleofector 2b, Nucleofector Kit L; Lonza, Basel, Switzerland). The GFP plasmid included in the electroporation kit was used to verify successful electroporation, and these cells were used as negative controls in Ussing chamber experiments. Cells were resuspended in a total volume of 700 μL, and 200 μL was seeded in each of three, collagen-coated polycarbonate membrane tissue-culture inserts (6.5 mm, 0.4 μm pore; Corning Transwell, Corning, NY, USA) with 400 μL media on the basolateral compartment. The next day, apical media were removed, and the basolateral media were replaced. After 7 days of culture in air-liquid interface conditions, cells were mounted in Ussing chambers for electrophysiology measurements.

HEK293 cell transfection

HEK293 cells were cultured in 5% FBS and 1% penicillin/streptomycin at 37°C in a 5% CO_2 humidified environment. 1×10^5 cells per well were seeded on a 6-well plate. The next day, 2 μg of pcDNA3.1(+) plasmid was transfected following the manufacturer's instructions for Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). When confluent, cells were harvested for mRNA or western blot analysis. A GFP control plasmid was used to verify successful transfection and to serve as a negative control in mRNA and western blot analyses.

Transduction and differentiation of primary human airway basal cells

All primary human airway epithelial cells were obtained from The University of Iowa *In Vitro* Models and Cell Culture Core under approval from The University of Iowa Institutional Review Board. De-identified cells isolated from donated non-CF lungs or discarded CF lungs after transplant were provided. 8×10^5 freshly isolated primary basal cells from CF donors were seeded on collagen-coated 10 cm plates in BronchiaLife Epithelial Basal Medium (Lifeline, Carlsbad, CA, USA). Once cells reached ∼80% confluency, cells were dissociated using TrypLE (Thermo Fisher Scientific/Gibco, Waltham, MA, USA), and 1×10^5 cells were seeded on collagen-coated polycarbonate membrane tissue-culture inserts (Corning Transwell; 6.5 mm, 0.4 μm pore), along with the viral vector and polybrene (2 μg/mL) in a final volume of 200 μL. 400 μL defined culture media (Ultroser G; Crescent Chemical, Islandia, NY, USA) were maintained in the basolateral compartment throughout the differentiation process.[77] Cells were maintained under submerged culture conditions for 48−72 h. Apical media were then removed, and cultures were maintained at air-liquid interface conditions for a minimum of 4 weeks. Once differentiated, cells were either mounted directly in Ussing chambers for electrophysiology analysis or dissociated for flow cytometry analysis using Accumax (Sigma-Aldrich, St. Louis, MO, USA). The following mutations were represented in the CF samples used in these studies: ΔF508, R75X, and 3,849 + 10 kb C > T.

For non-CF cells, 2×10^5 cells were seeded onto collagen-coated 6-well plates, along with viral vector and polybrene (2 μg/mL) in BronchiaLife Epithelial Basal Medium (1 mL final volume). Media were replaced as needed until cells reached confluency 3−5 days post-transduction and were harvested using TypLE for flow cytometry analysis.

Western blot analysis

Adherent cells in a 6-well plate were washed with PBS, and 0.5 mL radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific/Gibco, Waltham, MA, USA) with protease inhibitor (cOmplete ULTRA Tablets, Mini, EDTA-free; Roche, Basel, Switzerland) was added to each well. The plate was placed at −80°C for 10 min and then allowed to thaw at room temperature. Cell lysate was collected, and cell debris was separated by centrifugation. Protein-containing supernatant was collected and stored at −20°C. A bicinchoninic acid (BCA) assay (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific/Gibco, Waltham, MA, USA) was performed prior

to each western blot to quantify protein. 20 μg of protein per sample was loaded in a 3%–8% Criterion XT Tris-Acetate Gel (Bio-Rad, Hercules, CA, USA) and ran at 125 V for 90 min in Tris/tricine/SDS Running Buffer (Bio-Rad, Hercules, CA, USA). Transfer to Immobilon-FL polyvinylidene fluoride (PVDF) membrane (Millipore, Burlington, MA, USA) was performed at 110 μA, 4°C, overnight in high glycine transfer buffer (120 g glycine, 6 g Tris-base in 2 L water). The membrane was blocked with 0.1% Hammarsten casein in PBS for 1 h. Primary antibodies (mouse anti-human CFTR UNC-596 and rabbit anti-human vinculin; Thermo Fisher Scientific/Gibco, Waltham, MA, USA) were diluted 1:2,000 and incubated at room temperature for 2 h. Secondary IRDye antibodies (donkey anti-rabbit 680RD and donkey anti-mouse 800CW; LI-COR Biosciences, Lincoln, NE, USA) were diluted 1:20,000 and incubated for 1 h at room temperature. Three washes with Tris-buffered saline with Tween 20 (TBST) for 15 min were performed between each step. Membrane was imaged and analyzed using the LI-COR Biosciences Odyssey system.

mRNA measurements

Adherent cells in a 6-well plate were washed with PBS. Cell contents of each well were collected in 0.5 mL TRIzol (Invitrogen, Carlsbad, CA, USA). RNA was isolated following the manufacturer's instructions for Direct-zol RNA Kit (Zymo Research, Irvine, CA, USA). cDNA was generated using a High-Capacity-RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA), and qPCR (Applied Biosystems 7900HT, Foster City, CA, USA) was performed using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific/Gibco, Waltham, MA, USA) using primers directed against the polyadenylation sequence of pcDNA3.1(+) plasmids 5′-CTCGACTGTGCCTTC TAGTTG-3′ and 5′-GCACCTTCCAGGGTCAAG-3′. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to normalize gene expression using primers 5′-GGATTTGGTCGTATTGGG-3′ and 5′-GGATTTGGTCGTATTGGG-3′.

Flow cytometry

Cells were resuspended in 100 μL PBS containing 2% FBS with LIVE/DEAD Fixable Far Red Stain Kit (Invitrogen, Carlsbad, CA, USA) and incubated for 30 min protected from light. Three washes with 1 mL 2% FBS in PBS were performed before resuspending cells in a final volume of 500 μL for flow cytometry analysis in an Attune NxT Flow Cytometer (Invitrogen, Carlsbad, CA, USA). Doublets and dead cells were excluded from analysis.

Short circuit measurements

For transepithelial chloride current measurements, epithelial cultures were mounted in Ussing chambers; submerged in a solution containing 135 mM NaCl, 5 mM HEPES, 0.6 mM KH_2PO_4, 2.4 mM K_2HPO_4, 2.2 mM $MgCl_2$, 1.2 mM $CaCl_2$, and 5 mM dextrose; and bubbled with air. For bicarbonate measurements, cultures were submerged in a chloride-free solution composed of 118.9 mM Na gluconate, 25 mM $NaHCO_3$, 5 mM Ca gluconate, 1 mM Mg gluconate, 2.4 mM K_2HPO_4, 0.6 mM KH_2PO_4, and 5 mM dextrose and bubbled with CO_2. Amiloride, ENaC inhibitor, and DIDS, a Cl^- exchanger

inhibitor, were sequentially added apically to a final concentration of 100 μM. CFTR was then apically activated with the cyclic AMP agonists F&I at a final concentration of 10 μM and 100 μM, respectively. Finally, the CFTR inhibitor GlyH (Cystic Fibrosis Foundation) was added apically to a final concentration of 100 μM. ΔI_{SC}, in response to CFTR activation and inhibition, was calculated. For FRT transepithelial current measurements, a Cl^- gradient was used. Prior to F&I stimulation, the apical solution was replaced with one in which NaCl was replaced with $NaC_6H_{11}O_7$, and changes in current (ΔI_T) were calculated.

Patch-clamp experiments

Experiments were performed as previously described.[78] We used excised, inside-out membrane patches from HEK293T cells transiently expressing WT *CFTR* or co*CFTR3* using pcDNA3.1(+) vectors. The pipette (extracellular) solution contained the following: 140 mM N-methyl-D-glucamine, 3 mM $MgCl_2$, 5 mM $CaCl_2$, 100 mM L-aspartic acid, and 10 mM tricine (pH 7.3) with HCl. The bath (intracellular) solution contained 140 mM N-methyl-D-glucamine, 3 mM $MgCl_2$, 1 mM Cs ethylene glycol bis (2-aminoethyl ether)-N,N,N′,N′ tetraacetic acid (CsEGTA), and 10 mM tricine (pH 7.3) with HCl. Following patch excision, CFTR channels were activated with a 22-nM protein kinase A (PKA) catalytic subunit (from bovine heart; EMD Millipore, Billerica, MA, USA) and 1 mM ATP (magnesium salt; Sigma-Aldrich, St. Louis, MO, USA). The PKA catalytic subunit was present in all cytosolic solutions that contained ATP. Experiments were performed at room temperature (23°C -26°C). Recordings from patches containing 2$-$8 channels were digitized at 5 kHz and prior to analysis, low-pass filtered at 500 Hz using an 8-pole Bessel filter (Model 900; Frequency Devices, Haverhill, MA, USA). Single channel openings and closings were analyzed with a burst delimiter of 20 ms using Clampfit software (version 10.3; Molecular Devices, Sunnyvale, CA, USA).[79] Events <4 ms duration were ignored. The mean IBI was calculated using the formula $P_o = (BD \times P_{o,Burst})/(BD + IBI)$, where P_o is the mean open state probability and $P_{o,Burst}$ is the P_o within a burst.[80]

Statistics

All data were analyzed using GraphPad Prism 8 software (San Diego, CA, USA). Statistical significance was determined using one-way ANOVA with Dunn's multiple comparison test, one-way ANOVA on ranks (Kruskal-Wallis test) with Dunn's multiple comparisons test, or multiple t tests with Bonferroni-Dunn correction as appropriate. Error bars represent mean ± SE.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.omtm.2021.02.020.

AUTHOR CONTRIBUTIONS

Conceptualization, L.I.M.L., A.L.C., P.L.S., S.R., and P.B.M.; investigation, L.I.M.L. and Q.D.; writing – original draft, L.I.M.L.; writing – review & editing, L.I.M.L, A.L.C., Q.D., C.O.R., S.R., P.L.S., and P.B.M.; supervision, C.O.R., P.L.S., and P.B.M.

DECLARATION OF INTERESTS

P.B.M. is on the Scientific Advisory Board and receives support for sponsored research from Spirovant Sciences, Inc.

REFERENCES

1. Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.L., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.

2. Zabner, J., Couture, L.A., Gregory, R.J., Graham, S.M., Smith, A.E., and Welsh, M.J. (1993). Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207–216.

3. Zabner, J., Ramsey, B.W., Meeker, D.P., Aitken, M.L., Balfour, R.P., Gibson, R.L., Launspach, J., Moscicki, R.A., Richards, S.M., Standaert, T.A., et al. (1996). Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97, 1504–1511.

4. Moss, R.B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P.L., Clancy, J.P., Spencer, L.T., Pilewski, J., Waltz, D.A., Dorkin, H.L., et al. (2007). Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum. Gene Ther. 18, 726–732.

5. Wagner, J.A., Reynolds, T., Moran, M.L., Moss, R.B., Wine, J.J., Flotte, T.R., and Gardner, P. (1998). Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351, 1702–1703.

6. Alton, E.W.F.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield, E.V., Boyd, A.C., Brand, J., Buchan, R., Calcedo, R., et al.; UK Cystic Fibrosis Gene Therapy Consortium (2015). Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 684–691.

7. Davies, G., Davies, J.C., Gill, D.R., Hyde, S.C., Boyd, C., Innes, J.A., Porteous, D.J., Cheng, S.H., Scheule, R.K., Higgins, T., et al. (2011). T4: Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis. Thorax 66 (Suppl 4), A2.

8. Hyde, S.C., Southern, K.W., Gileadi, U., Fitzjohn, E.M., Mofford, K.A., Waddell, B.E., Gooi, H.C., Goddard, C.A., Hannavy, K., Smyth, S.E., et al. (2000). Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 7, 1156–1165.

9. Limberis, M., Anson, D.S., Fuller, M., and Parsons, D.W. (2002). Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum. Gene Ther. 13, 1961–1970.

10. Cooney, A.L., Abou Alaiwa, M.H., Shah, V.S., Bouzek, D.C., Stroik, M.R., Powers, L.S., Gansemer, N.D., Meyerholz, D.K., Welsh, M.J., Stoltz, D.A., et al. (2016). Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight 1, e88730.

11. Farrow, N., Miller, D., Cmielewski, P., Donnelley, M., Bright, R., and Parsons, D.W. (2013). Airway gene transfer in a non-human primate: lentiviral gene expression in marmoset lungs. Sci. Rep. 3, 1287.

12. Burns, J.C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033–8037.

13. Borok, Z., Harboe-Schmidt, J.E., Brody, S.L., You, Y., Zhou, B., Li, X., Cannon, P.M., Kim, K.J., Crandall, E.D., and Kasahara, N. (2001). Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. J. Virol. 75, 11747–11754.

14. Sinn, P.L., Cooney, A.L., Oakland, M., Dylla, D.E., Wallen, T.J., Pezzulo, A.A., Chang, E.H., and McCray, P.B., Jr. (2012). Lentiviral vector gene transfer to porcine airways. Mol. Ther. Nucleic Acids 1, e56.

15. Cmielewski, P., Farrow, N., Devereux, S., Parsons, D., and Donnelley, M. (2017). Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways. Exp. Lung Res. 43, 426–433.

16. Johnson, L.G., Olsen, J.C., Naldini, L., and Boucher, R.C. (2000). Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 7, 568–574.

17. Wang, G., Zabner, J., Deering, C., Launspach, J., Shao, J., Bodner, M., Jolly, D.J., Davidson, B.L., and McCray, P.B., Jr. (2000). Increasing epithelial junction permeability enhances gene transfer to airway epithelia In vivo. Am. J. Respir. Cell Mol. Biol. 22, 129–138.

18. Kobinger, G.P., Weiner, D.J., Yu, Q.C., and Wilson, J.M. (2001). Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19, 225–230.

19. Sinn, P.L., Coffin, J.E., Ayithan, N., Holt, K.H., and Maury, W. (2017). Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins. Methods Mol. Biol. 1628, 65–78.

20. Sinn, P.L., Hwang, B.Y., Li, N., Ortiz, J.L.S., Shirazi, E., Parekh, K.R., Cooney, A.L., Schaffer, D.V., and McCray, P.B., Jr. (2017). Novel GP64 envelope variants for improved delivery to human airway epithelial cells. Gene Ther. 24, 674–679.

21. Patel, M., Giddings, A.M., Sechelski, J., and Olsen, J.C. (2013). High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors. J. Gene Med. 15, 51–62.

22. Griesenbach, U., Inoue, M., Meng, C., Farley, R., Chan, M., Newman, N.K., Brum, A., You, J., Kerton, A., Shoemark, A., et al. (2012). Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am. J. Respir. Crit. Care Med. 186, 846–856.

23. Mitomo, K., Griesenbach, U., Inoue, M., Somerton, L., Meng, C., Akiba, E., Tabata, T., Ueda, Y., Frankel, G.M., Farley, R., et al. (2010). Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol. Ther. 18, 1173–1182.

24. Kobayashi, M., Iida, A., Ueda, Y., and Hasegawa, M. (2003). Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J. Virol. 77, 2607–2614.

25. Bou Saab, J., Losa, D., Chanson, M., and Ruez, R. (2014). Connexins in respiratory and gastrointestinal mucosal immunity. FEBS Lett. 588, 1288–1296.

26. Chanson, M., Kotsias, B.A., Peracchia, C., and O'Grady, S.M. (2007). Interactions of connexins with other membrane channels and transporters. Prog. Biophys. Mol. Biol. 94, 233–244.

27. Scheckenbach, K.E., Losa, D., Dudez, T., Bacchetta, M., O'Grady, S., Crespin, S., and Chanson, M. (2011). Prostaglandin E2 regulation of cystic fibrosis transmembrane conductance regulator activity and airway surface liquid volume requires gap junctional communication. Am. J. Respir. Cell Mol. Biol. 44, 74–82.

28. Sanderson, M.J., Chow, I., and Dirksen, E.R. (1988). Intercellular communication between ciliated cells in culture. Am. J. Physiol. 254, C63–C74.

29. Kreda, S.M., Mall, M., Mengos, A., Rochelle, L., Yankaskas, J., Riordan, J.R., and Boucher, R.C. (2005). Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol. Biol. Cell 16, 2154–2167.

30. Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F., Chen, S., Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560, 319–324.

31. Plasschaert, L.W., Žilionis, R., Choo-Wing, R., Savova, V., Knehr, J., Roma, G., Klein, A.M., and Jaffe, A.B. (2018). A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature 560, 377–381.

32. Okuda, K., Dang, H., Kobayashi, Y., Carraro, G., Nakano, S., Chen, G., Kato, T., Asakura, T., Gilmore, R.C., Morton, L.C., et al. (2020). Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia. Am. J. Respir. Crit. Care Med. Published online December 15, 2020. https://doi.org/10.1164/rccm.202008-3198OC.

33. Qin, J.Y., Zhang, L., Clift, K.L., Hulur, I., Xiang, A.P., Ren, B.Z., and Lahn, B.T. (2010). Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE 5, e10611.

34. Cheng, L., Ziegelhoffer, P.R., and Yang, N.S. (1993). In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. USA 90, 4455–4459.

35. Farmen, S.L., Karp, P.H., Ng, P., Palmer, D.J., Koehler, D.R., Hu, J., Beaudet, A.L., Zabner, J., and Welsh, M.J. (2005). Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L1123–L1130.

36. Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., and Baum, C. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718–725.

37. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, L., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687–696.

38. Stein, S., Ott, M.G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198–204.

39. Río, P., Navarro, S., Wang, W., Sánchez-Domínguez, R., Pujol, R.M., Segovia, J.C., Bogliolo, M., Merino, E., Wu, N., Salgado, R., et al. (2019). Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nat. Med. 25, 1396–1401.

40. Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.

41. De Ravin, S.S., Wu, X., Moir, S., Anaya-O'Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., Marquesen, M., et al. (2016). Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 8, 335ra57.

42. Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L.J., Salvetti, A.P., Fischer, M.D., Aylward, J.W., Barnard, A.R., et al. (2020). Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat. Med. 26, 354–359.

43. Fischer, M.D., McClements, M.E., Martinez-Fernandez de la Camara, C., Bellingrath, J.S., Dauletbekov, D., Ramsden, S.C., Hickey, D.G., Barnard, A.R., and MacLaren, R.E. (2017). Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa. Mol. Ther. 25, 1854–1865.

44. Kohn, D.B., Booth, C., Kang, E.M., Pai, S.Y., Shaw, K.L., Santilli, G., Armant, M., Buckland, K.F., Choi, U., De Ravin, S.S., et al.; Net4CGD consortium (2020). Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat. Med. 26, 200–206.

45. Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994–2004.

46. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357–2365.

47. Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N. Engl. J. Med. *377*, 2519–2530.

48. Dittmar, K.A., Goodenbour, J.M., and Pan, T. (2006). Tissue-specific differences in human transfer RNA expression. PLoS Genet. *2*, e221.

49. Kudla, G., Lipinski, L., Caffin, F., Helwak, A., and Zylicz, M. (2006). High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. *4*, e180.

50. Elhaik, E., and Tatarinova, T. (2012). GC3 biology in eukaryotes and prokaryotes. In DNA Methylation - From Genomics to Technology, T. Tatarinova, ed. (InTech), pp. 3–68.

51. Gebert, D., Jehn, J., and Rosenkranz, D. (2019). Widespread selection for extremely high and low levels of secondary structure in coding sequences across all domains of life. Open Biol. *9*, 190020.

52. Bauer, A.P., Leikam, D., Krinner, S., Notka, F., Ludwig, C., Längst, G., and Wagner, R. (2010). The impact of intragenic CpG content on gene expression. Nucleic Acids Res. *38*, 3891–3908.

53. Sharp, P.M., and Li, W.H. (1987). The codon Adaptation Index–a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. *15*, 1281–1295.

54. Kim, S.J., Yoon, J.S., Shishido, H., Yang, Z., Rooney, L.A., Barral, J.M., and Skach, W.R. (2015). Protein folding. Translational tuning optimizes nascent protein folding in cells. Science *348*, 444–448.

55. Grote, A., Hiller, K., Scheer, M., Münch, R., Nörtemann, B., Hempel, D.C., and Jahn, D. (2005). JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. *33*, W526–W531.

56. Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White, G.A., O'Riordan, C.R., and Smith, A.E. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell *63*, 827–834.

57. Sheppard, D.N., Carson, M.R., Ostedgaard, L.S., Denning, G.M., and Welsh, M.J. (1994). Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am. J. Physiol. *266*, L405–L413.

58. Baumlin-Schmid, N., Salathe, M., and Fregien, N.L. (2016). Optimal Lentivirus Production and Cell Culture Conditions Necessary to Successfully Transduce Primary Human Bronchial Epithelial Cells. J. Vis. Exp. (113), e54176.

59. Bartoszewski, R., Króliczewski, J., Piotrowski, A., Jasiecka, A.J., Bartoszewska, S., Vecchio-Pagan, B., Fu, L., Sobolewska, A., Matalon, S., Cutting, G.R., et al. (2016). Codon bias and the folding dynamics of the cystic fibrosis transmembrane conductance regulator. Cell. Mol. Biol. Lett. *21*, 23.

60. Walsh, I.M., Bowman, M.A., Soto Santarriaga, I.F., Rodriguez, A., and Clark, P.L. (2020). Synonymous codon substitutions perturb cotranslational protein folding in vivo and impair cell fitness. Proc. Natl. Acad. Sci. USA *117*, 3528–3534.

61. Goldman, M.J., Yang, Y., and Wilson, J.M. (1995). Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat. Genet. *9*, 126–131.

62. Johnson, L.G., Olsen, J.C., Sarkadi, B., Moore, K.L., Swanstrom, R., and Boucher, R.C. (1992). Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. *2*, 21–25.

63. Shah, V.S., Ernst, S., Tang, X.X., Karp, P.H., Parker, C.P., Ostedgaard, L.S., and Welsh, M.J. (2016). Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies. Proc. Natl. Acad. Sci. USA *113*, 5382–5387.

64. Zhang, L., Button, B., Gabriel, S.E., Burkett, S., Yan, Y., Skiadopoulos, M.H., Dang, Y.L., Vogel, L.N., McKay, T., Mengos, A., et al. (2009). CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. *7*, e1000155.

65. Frizzell, R.A., and Hanrahan, J.W. (2012). Physiology of epithelial chloride and fluid secretion. Cold Spring Harb. Perspect. Med. *2*, a009563.

66. Moreno-Carranza, B., Gentsch, M., Stein, S., Schambach, A., Santilli, G., Rudolf, E., Ryser, M.F., Haria, S., Thrasher, A.J., Baum, C., et al. (2009). Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. *16*, 111–118.

67. Ward, N.J., Buckley, S.M., Waddington, S.N., Vandendriessche, T., Chuah, M.K., Nathwani, A.C., McIntosh, J., Tuddenham, E.G., Kinnon, C., Thrasher, A.J., and McVey, J.H. (2011). Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood *117*, 798–807.

68. Zhang, R., Wang, Q., Zhang, L., and Chen, S. (2015). Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B. Front. Med. *9*, 90–99.

69. Padegimas, L., Kowalczyk, T.H., Adams, S., Gedeon, C.R., Oette, S.M., Dines, K., Hyatt, S.L., Sesenoglu-Laird, O., Tyr, O., Moen, R.C., and Cooper, M.J. (2012). Optimization of hCFTR lung expression in mice using DNA nanoparticles. Mol. Ther. *20*, 63–72.

70. al Yacoub, N., Romanowska, M., Haritonova, N., and Foerster, J. (2007). Optimized production and concentration of lentiviral vectors containing large inserts. J. Gene Med. *9*, 579–584.

71. Kumar, M., Keller, B., Makalou, N., and Sutton, R.E. (2001). Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. *12*, 1893–1905.

72. Berical, A., Lee, R.E., Randell, S.H., and Hawkins, F. (2019). Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis. Front. Pharmacol. *10*, 74.

73. Smit, L.S., Wilkinson, D.J., Mansoura, M.K., Collins, F.S., and Dawson, D.C. (1993). Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci. USA *90*, 9963–9967.

74. Baker, J.M., Hudson, R.P., Kanelis, V., Choy, W.Y., Thibodeau, P.H., Thomas, P.J., and Forman-Kay, J.D. (2007). CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat. Struct. Mol. Biol. *14*, 738–745.

75. Romero, Z., Campo-Fernandez, B., Wherley, J., Kaufman, M.L., Urbinati, F., Cooper, A.R., Hoban, M.D., Baldwin, K.M., Lumaquin, D., Wang, X., et al. (2015). The human ankyrin 1 promoter insulator sustains gene expression in a β-globin lentiviral vector in hematopoietic stem cells. Mol. Ther. Methods Clin. Dev. *2*, 15012.

76. Breda, L., Casu, C., Gardenghi, S., Bianchi, N., Cartegni, L., Narla, M., Yazdanbakhsh, K., Musso, M., Manwani, D., Little, J., et al. (2012). Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. PLoS ONE *7*, e32345.

77. Karp, P.H., Moninger, T.O., Weber, S.P., Nesselhauf, T.S., Launspach, J.L., Zabner, J., and Welsh, M.J. (2002). An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol. Biol. *188*, 115–137.

78. Dong, Q., Randak, C.O., and Welsh, M.J. (2008). A mutation in CFTR modifies the effects of the adenylate kinase inhibitor Ap5A on channel gating. Biophys. J. *95*, 5178–5185.

79. Carson, M.R., Travis, S.M., and Welsh, M.J. (1995). The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. J. Biol. Chem. *270*, 1711–1717.

80. Cotten, J.F., and Welsh, M.J. (1998). Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. *273*, 31873–31879.